Closing and Opening Holes in the Glycan Shield of HIV-1 Envelope Glycoprotein SOSIP Trimers Can Redirect the Neutralizing Antibody Response to the Newly Unmasked Epitopes
暂无分享,去创建一个
Andrew B. Ward | Ian A. Wilson | David C. Montefiori | John P. Moore | I. Wilson | D. Montefiori | T. Ketas | A. Ward | R. Sanders | M. V. van Gils | C. Cottrell | G. Ozorowski | C. Labranche | M. Crispin | P. Klasse | Rajesh P. Ringe | Sonu Kumar | Christopher A. Cottrell | Pavel Pugach | Celia C. LaBranche | Gemma E. Seabright | Thomas J. Ketas | Gabriel Ozorowski | Sonu Kumar | Anna Schorcht | Marit J. van Gils | Max Crispin | Rogier W. Sanders | P. J. Klasse | A. Schorcht | P. Pugach | Marit J. van Gils
[1] John P. Moore,et al. Sequential and Simultaneous Immunization of Rabbits with HIV-1 Envelope Glycoprotein SOSIP.664 Trimers from Clades A, B and C , 2016, PLoS pathogens.
[2] P. Kwong,et al. How HIV-1 entry mechanism and broadly neutralizing antibodies guide structure-based vaccine design , 2017, Current opinion in HIV and AIDS.
[3] John P. Moore,et al. Reducing V3 Antigenicity and Immunogenicity on Soluble, Native-Like HIV-1 Env SOSIP Trimers , 2017, Journal of Virology.
[4] U. Baxa,et al. Soluble Prefusion Closed DS-SOSIP.664-Env Trimers of Diverse HIV-1 Strains. , 2017, Cell reports.
[5] Cinque S. Soto,et al. Quantification of the Impact of the HIV-1-Glycan Shield on Antibody Elicitation. , 2017, Cell reports.
[6] Tongqing Zhou,et al. Identification of a CD4-Binding-Site Antibody to HIV that Evolved Near-Pan Neutralization Breadth. , 2016, Immunity.
[7] John P. Moore,et al. Molecular Architecture of the Cleavage-Dependent Mannose Patch on a Soluble HIV-1 Envelope Glycoprotein Trimer , 2016, Journal of Virology.
[8] J. Mascola,et al. Epitope-based vaccine design yields fusion peptide-directed antibodies that neutralize diverse strains of HIV-1 , 2018, Nature Medicine.
[9] John P. Moore,et al. Differential binding of neutralizing and non-neutralizing antibodies to native-like soluble HIV-1 Env trimers, uncleaved Env proteins, and monomeric subunits , 2014, Retrovirology.
[10] G. Debnath,et al. D-101 HIV-1 neutralizing antibodies induced by native-like envelope trimers , 2016 .
[11] Ian A Wilson,et al. The HIV‐1 envelope glycoprotein structure: nailing down a moving target , 2017, Immunological reviews.
[12] John P. Moore,et al. Asymmetric recognition of the HIV-1 trimer by broadly neutralizing antibody PG9 , 2013, Proceedings of the National Academy of Sciences.
[13] J. Mascola,et al. HIV-1 Vaccines Based on Antibody Identification, B Cell Ontogeny, and Epitope Structure. , 2018, Immunity.
[14] Udo Albus,et al. Book Review: Guide for the Care and use of Laboratory Animals , 1998 .
[15] John P. Moore,et al. A Next-Generation Cleaved, Soluble HIV-1 Env Trimer, BG505 SOSIP.664 gp140, Expresses Multiple Epitopes for Broadly Neutralizing but Not Non-Neutralizing Antibodies , 2013, PLoS pathogens.
[16] Jennifer S. Wood,et al. Direct Probing of Germinal Center Responses Reveals Immunological Features and Bottlenecks for Neutralizing Antibody Responses to HIV Env Trimer. , 2016, Cell reports.
[17] Raphael Gottardo,et al. Global Panel of HIV-1 Env Reference Strains for Standardized Assessments of Vaccine-Elicited Neutralizing Antibodies , 2013, Journal of Virology.
[18] J. Moore,et al. Quantitative model of antibody- and soluble CD4-mediated neutralization of primary isolates and T-cell line-adapted strains of human immunodeficiency virus type 1 , 1996, Journal of virology.
[19] John P. Moore,et al. Cryo-EM Structure of a Fully Glycosylated Soluble Cleaved HIV-1 Envelope Trimer , 2013, Science.
[20] John P. Moore,et al. Design and structure of two HIV-1 clade C SOSIP.664 trimers that increase the arsenal of native-like Env immunogens , 2015, Proceedings of the National Academy of Sciences.
[21] John P. Moore,et al. Murine Antibody Responses to Cleaved Soluble HIV-1 Envelope Trimers Are Highly Restricted in Specificity , 2015, Journal of Virology.
[22] John P. Moore,et al. How can HIV-type-1-Env immunogenicity be improved to facilitate antibody-based vaccine development? , 2012, AIDS research and human retroviruses.
[23] S. Munir Alam,et al. Antibody‐virus co‐evolution in HIV infection: paths for HIV vaccine development , 2017, Immunological reviews.
[24] L. Stamatatos,et al. Design and crystal structure of a native-like HIV-1 envelope trimer that engages multiple broadly neutralizing antibody precursors in vivo , 2017, The Journal of experimental medicine.
[25] Q. Sattentau,et al. The Carbomer-Lecithin Adjuvant Adjuplex Has Potent Immunoactivating Properties and Elicits Protective Adaptive Immunity against Influenza Virus Challenge in Mice , 2015, Clinical and Vaccine Immunology.
[26] M. Nussenzweig,et al. Progress toward active or passive HIV-1 vaccination , 2017, The Journal of experimental medicine.
[27] D. Kabat,et al. Kinetic mechanism for HIV-1 neutralization by antibody 2G12 entails reversible glycan binding that slows cell entry , 2012, Proceedings of the National Academy of Sciences.
[28] I. Wilson,et al. Co-evolution of HIV Envelope and Apex-Targeting Neutralizing Antibody Lineage Provides Benchmarks for Vaccine Design , 2018, Cell reports.
[29] P. Klasse. Modeling how many envelope glycoprotein trimers per virion participate in human immunodeficiency virus infectivity and its neutralization by antibody. , 2007, Virology.
[30] Ian A Wilson,et al. Structure and Immune Recognition of the HIV Glycan Shield. , 2018, Annual review of biophysics.
[31] David J. Harvey,et al. Site-Specific Glycosylation of Virion-Derived HIV-1 Env Is Mimicked by a Soluble Trimeric Immunogen , 2018, Cell reports.
[32] A. Ward,et al. Cryo-EM structure of a native, fully glycosylated, cleaved HIV-1 envelope trimer , 2016, Science.
[33] Conrad C. Huang,et al. UCSF Chimera—A visualization system for exploratory research and analysis , 2004, J. Comput. Chem..
[34] Lloyd H. Michael,et al. The Guide for the Care and Use of Laboratory Animals. , 2016, ILAR journal.
[35] John P. Moore,et al. Native‐like Env trimers as a platform for HIV‐1 vaccine design , 2017, Immunological reviews.
[36] John P. Moore,et al. Immunogenicity of Stabilized HIV-1 Envelope Trimers with Reduced Exposure of Non-neutralizing Epitopes , 2015, Cell.
[37] A. Trkola,et al. MPER-specific antibodies induce gp120 shedding and irreversibly neutralize HIV-1 , 2011, The Journal of experimental medicine.
[38] J. Mascola,et al. Adjuvants and the vaccine response to the DS-Cav1-stabilized fusion glycoprotein of respiratory syncytial virus , 2017, PloS one.
[39] Holly Janes,et al. Tiered Categorization of a Diverse Panel of HIV-1 Env Pseudoviruses for Assessment of Neutralizing Antibodies , 2009, Journal of Virology.
[40] D. Burton,et al. A Broadly Neutralizing Antibody Targets the Dynamic HIV Envelope Trimer Apex via a Long, Rigidified, and Anionic β-Hairpin Structure , 2017, Immunity.
[41] Ryan McBride,et al. Broadly Neutralizing Antibody PGT121 Allosterically Modulates CD4 Binding via Recognition of the HIV-1 gp120 V3 Base and Multiple Surrounding Glycans , 2013, PLoS pathogens.
[42] K. Kirti,et al. Colorful World of Microbes: Carotenoids and Their Applications , 2014 .
[43] L. Stamatatos,et al. Germline‐targeting immunogens , 2017, Immunological reviews.
[44] J. Mascola,et al. Immunogenicity of a Prefusion HIV-1 Envelope Trimer in Complex with a Quaternary-Structure-Specific Antibody , 2015, Journal of Virology.
[45] Daniel W. Kulp,et al. Vaccine-Elicited Tier 2 HIV-1 Neutralizing Antibodies Bind to Quaternary Epitopes Involving Glycan-Deficient Patches Proximal to the CD4 Binding Site , 2015, PLoS pathogens.
[46] Inhibition of Virus Attachment to CD4+ Target Cells Is a Major Mechanism of T Cell Line–adapted HIV-1 Neutralization , 1997, The Journal of experimental medicine.
[47] John P. Moore,et al. Immunogenicity in Rabbits of HIV-1 SOSIP Trimers from Clades A, B, and C, Given Individually, Sequentially, or in Combination , 2018, Journal of Virology.
[48] D. Montefiori,et al. Neutralization tiers of HIV-1 , 2017, Current opinion in HIV and AIDS.
[49] Daniel W. Kulp,et al. Elicitation of Robust Tier 2 Neutralizing Antibody Responses in Nonhuman Primates by HIV Envelope Trimer Immunization Using Optimized Approaches , 2017, Immunity.
[50] Weston B Struwe,et al. Composition and Antigenic Effects of Individual Glycan Sites of a Trimeric HIV-1 Envelope Glycoprotein , 2016, Cell reports.
[51] Florian Klein,et al. Antibodies in HIV-1 Vaccine Development and Therapy , 2013, Science.
[52] Tongqing Zhou,et al. Structure-Based Design of a Soluble Prefusion-Closed HIV-1 Env Trimer with Reduced CD4 Affinity and Improved Immunogenicity , 2017, Journal of Virology.
[53] Tongqing Zhou,et al. Structure and immune recognition of trimeric prefusion HIV-1 Env , 2014, Nature.
[54] B. Pulendran,et al. Epitopes for neutralizing antibodies induced by HIV-1 envelope glycoprotein BG505 SOSIP trimers in rabbits and macaques , 2018, PLoS pathogens.
[55] J. Berzofsky. Intrinsic and extrinsic factors in protein antigenic structure. , 1985, Science.
[56] John P. Moore,et al. Integrity of Glycosylation Processing of a Glycan-Depleted Trimeric HIV-1 Immunogen Targeting Key B-Cell Lineages. , 2018, Journal of proteome research.
[57] P. Klasse,et al. Neutralization of Virus Infectivity by Antibodies: Old Problems in New Perspectives. , 2014, Advances in biology.
[58] G. Air,et al. Epitopes on protein antigens: Misconceptions and realities , 1990, Cell.
[59] Bette Korber,et al. Completeness of HIV-1 Envelope Glycan Shield at Transmission Determines Neutralization Breadth , 2018, Cell reports.
[60] John R Yates,et al. Global site-specific N-glycosylation analysis of HIV envelope glycoprotein , 2017, Nature Communications.
[61] R. Sanders,et al. Targeting B-cell germlines and focusing affinity maturation: the next hurdles in HIV-1-vaccine development? , 2014, Expert review of vaccines.
[62] William R. Schief,et al. Glycan clustering stabilizes the mannose patch of HIV-1 and preserves vulnerability to broadly neutralizing antibodies , 2015, Nature Communications.
[63] John P. Moore,et al. A Native-Like SOSIP.664 Trimer Based on an HIV-1 Subtype B env Gene , 2015, Journal of Virology.
[64] Gwo-Yu Chuang,et al. Broad and potent HIV-1 neutralization by a human antibody that binds the gp41-120 interface , 2014, Nature.
[65] Daniel W. Kulp,et al. Structure-based design of native-like HIV-1 envelope trimers to silence non-neutralizing epitopes and eliminate CD4 binding , 2017, Nature Communications.
[66] John P. Moore,et al. Crystal Structure of a Soluble Cleaved HIV-1 Envelope Trimer , 2013, Science.
[67] Q. Sattentau,et al. Neutralization of Human Immunodeficiency Virus Type 1 by Antibody to gp120 Is Determined Primarily by Occupancy of Sites on the Virion Irrespective of Epitope Specificity , 1998, Journal of Virology.
[68] E. Go,et al. Improving the Immunogenicity of Native-like HIV-1 Envelope Trimers by Hyperstabilization , 2017, Cell reports.
[69] R. Wyatt,et al. Targeted N-glycan deletion at the receptor-binding site retains HIV Env NFL trimer integrity and accelerates the elicited antibody response , 2017, PLoS pathogens.
[70] P. Klasse. The molecular basis of HIV entry , 2012, Cellular microbiology.